$4.47
+8.5%OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
OKUR • NASDAQ
| OnKure Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-59.5M | -52.7M | -35.3M | -29.5M | -39.8M | -19.5M | |
830K | 662K | 560K | 387K | 50K | 37K | |
11.6M | 4.5M | 199K | 48K | 0.0 | 0.0 | |
6K | 316K | 0.0 | 0.0 | 4.5M | 378K | |
-4.8M | -4M | 6K | 2.1M | -2.8M | 514K | |
-51.8M | -51.1M | -34.5M | -27M | -38M | -18.5M | |
INVESTING ACTIVITIES | ||||||
-46K | -52K | -246K | -1.1M | -198K | -24K | |
(0.0) | (0.0) | (0.0) | (0.0) | -31.4M | (0.0) | |
0.0 | 15.9M | 0.0 | 44.1M | 8.2M | 7.4M | |
0.0 | 0.0 | 0.0 | -44.1M | 0.0 | 0.0 | |
-46K | (15.9M) | -246K | -1.1M | -23.4M | (7.4M) | |
FINANCING ACTIVITIES | ||||||
203K | 58.9M | 65K | 340K | 132.4M | 47.3M | |
0.0 | 6M | 0.0 | 0.0 | 0.0 | 0.0 | |
-40K | 51.2M | -723K | -1.4M | 0.0 | 0.0 | |
163K | 116.1M | 53.1M | 26.5M | 132.4M | 47.3M | |
CASH FLOW SUMMARY | ||||||
-51.7M | 80.9M | 18.3M | -1.6M | 71M | 36.1M | |
110.8M | 29.9M | 11.5M | 13.2M | 53.6M | 17.5M | |
59.1M | 110.8M | 29.9M | 11.5M | 124.7M | 53.6M | |
-51.9M | -51.2M | -34.8M | -28.1M | -38.2M | -18.6M |
OKUR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | April 24, 2026 | April 24, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
S-3 S-3 N/A | November 06, 2025 | November 06, 2025 | ||
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Continue your OKUR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.